xten peptide protein XTEN - A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner peptides XTEN Peptide Protein: Revolutionizing Therapeutic Lifespans

XTEN protein The field of biopharmaceuticals is constantly seeking innovative solutions to enhance the efficacy and delivery of therapeutic agents. Among these advancements, the XTEN peptide protein has emerged as a significant development, offering a novel approach to extend the in vivo half-life of peptides and proteins.The present invention relates toextended recombinant polypeptide (XTEN) compositions, conjugate compositions comprising XTEN and XTEN linked to ... This extended recombinant polypeptide (XTEN) compositions technology is fundamentally altering how we conceive of drug longevity and therapeutic impact.

At its core, XTEN is a class of unstructured, hydrophilic, and biodegradable protein polymer designed to overcome the pharmacokinetic limitations of many existing therapeutics.XTEN as Biological Alternative to PEGylation Allows Complete ... Unlike traditional methods, XTEN is genetically fused to the therapeutic molecule, creating a single, larger entity. This fusion strategy leverages the inherent properties of XTEN to significantly prolong the time a therapeutic agent remains active in the body. The XTEN sequence itself is characterized by its lack of specific secondary or tertiary structure, rendering it a flexible and adaptable fusion partner.

The scientific literature highlights the XTEN protein as an unstructured, nonrepetitive protein polymerGenetically Encoded XTEN‐based Hydrogels with Tunable .... This structural characteristic is crucial to its function. By increasing the hydrodynamic volume and exhibiting a negative charge, XTEN conjugates are less susceptible to rapid renal clearance and enzymatic degradation. This results in a substantially longer presence in the bloodstream, allowing for less frequent dosing and potentially improved patient compliance. Research by Podust and colleagues has repeatedly demonstrated that XTEN polymers, such as XTEN144 and XTEN288, can effectively increase the half-lives of various biologically active molecules.

A key advantage of the XTEN peptide protein is its inherent low immunogenicity. Comprised of a specific set of amino acids, including A, E, G, P, S, and T, organized into 36-residue pseudorepeats of only six amino acids, XTEN lacks the hydrophobic residues that often trigger adverse immune responses. This safe and nonimmunogenic profile is critical for therapeutic applications, minimizing the risk of antibody formation and ensuring the sustained therapeutic effect of the fused protein or peptide.Xten conjugate compositions and methods of making same Studies have shown that XTEN has proven to be safe and nonimmunogenic in several animal species, with XTEN-modified drugs even entering clinical trials.Evolution of peptide half-life extension technologies and ...

The versatility of the XTEN technology is evident in its application across a wide range of therapeutic areas. For instance, Glucagon-like peptide 2 (GLP2), an intestinal growth factor, has been engineered with XTEN to enhance its therapeutic potential in treating intestinal diseases. Similarly, GLP-1 receptor agonists, vital for diabetes management, have been improved through the incorporation of XTEN sequences, leading to novel long-acting formulations. The ability to genetically fuse XTEN to a protein drug or peptide using recombinant technology offers a powerful platform for drug development.

Furthermore, the XTENlinker sequence can be tailored to optimize the properties of the conjugate. This tunability allows researchers to fine-tune the half-life extension and solubility of the therapeutic payloadExtension of in vivo half-life of biologically active molecules .... For example, studies have explored multivalent antiviral XTEN–peptide conjugates with long in vivo half-life and enhanced solubility, demonstrating the adaptability of the platform. The XTEN polymer itself can be engineered to specific lengths, such as the XTEN864-HGV-Apoptin fusion protein, to achieve desired pharmacokinetic profiles.Extension of in vivo half-life of biologically active molecules ...

The manufacturing process for XTEN is also a significant consideration2014年10月28日—XTEN is a proprietary recombinant polypeptide thatextends the in vivo half-life of therapeutics payloads. XTEN consists of naturally occurring .... The XTEN sequence has been specifically designed for good manufacturability, enabling its production in systems like *E. coli*.2009年11月16日—TheXTENsequence has been specifically designed to have low immunogenicity and good manufacturability, making it a generic platform technology ... This contrasts with some other half-life extension technologies that can be more complex and costly to produce. The development of XTEN-based hydrogels further showcases the material science applications of this protein polymerXTEN-Annexin A5: XTEN Allows Complete Expression of ....

In essence, the XTEN peptide protein represents a significant leap forward in biopharmaceutical engineering. By providing a robust, unstructured hydrophilic, biodegradable protein polymer that can be genetically fused to therapeutic agents, XTEN effectively extends the in vivo half-life of therapeutics payloads and peptides, offering a promising avenue for developing more effective and patient-friendly treatments. The ongoing research and development surrounding XTEN underscore its potential to revolutionize the landscape of therapeutic drug delivery.